Trial IRCT20150303021315N24 ; NCT05005559
Publication Tabarsi P, Clin Microbiol Infect, 2022
Primary outcome on the report: Occurrence of symptomatic COVID-19 starting from 14 days after the second dose. Primary events were defined as participants with at least one positive Polymerase chain reaction (PCR) test and any two or more of fever, chills, myalgia, headache, sore throat, nausea, vomiting, diarrhea, rhinorrhea, new-onset anosmia or ageusia or at least one positive PCR test and any one or more of the following respiratory signs and symptoms: cough, shortness of breath, and clinical or radiographic evidence of pneumonia starting 2 weeks after the second dose.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.